Amedeo Smart

Free Medical Literature Service

 

Amedeo

Parkinson's Disease
  Free Subscription

Articles published in
Mov Disord
    September 2025
  1. FAN Y, Hu Z, Yan QQ, Wan JJ, et al
    Reply to "Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals".
    Mov Disord. 2025 Sep 24. doi: 10.1002/mds.70060.
    >> Share

  2. MARTIN-BORNEZ M, Shar N, Nour MA, Murphy D, et al
    Does COMT Play a Role in Parkinson's Disease Susceptibility across Diverse Ancestral Populations?
    Mov Disord. 2025 Sep 23. doi: 10.1002/mds.70040.
    >> Share

  3. ZHAO Y, Pan H, Wang Y, Chen J, et al
    Expanding the Autosomal Recessive Gene Spectrum of Parkinson's Disease: A Study within the CPD10KGP.
    Mov Disord. 2025 Sep 17. doi: 10.1002/mds.70039.
    >> Share

  4. TAY YW, Ooi JCE, Lim SY, Chia YK, et al
    Very High Frequency of Early-Onset Parkinson's Disease and PRKN Mutations among Indigenous Patients in Sabah, Malaysia.
    Mov Disord. 2025 Sep 15. doi: 10.1002/mds.70015.
    >> Share

  5. VIDENOVIC A, Coffey CS, Klerman EB, Cudkowicz M, et al
    ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70009.
    >> Share

  6. ZHAO H, Hao S, Zhang P, He S, et al
    Cortical and Corticomuscular Beta-Gamma Phase-Amplitude Coupling During Different Locomotion States and the Effects of Levodopa in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70031.
    >> Share

  7. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    >> Share

  8. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    >> Share

  9. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    >> Share

  10. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    >> Share

    August 2025
  11. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    >> Share

  12. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
    Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
    Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
    >> Share

  13. ROSSI M, Farris CM, Baiardi S, Giannini G, et al
    Comparison of Two alpha-Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism.
    Mov Disord. 2025 Aug 20. doi: 10.1002/mds.70017.
    >> Share

  14. YIN KF, Gu XJ, Yu JM, Su WM, et al
    Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
    Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
    >> Share

  15. IGNATAVICIUS A, Churchill L, Anderson J, Konuri A, et al
    Combined Dysfunction of the Amygdala and Nucleus Basalis Underlies Visual Hallucinations in Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.70011.
    >> Share

  16. FLORES-TORRES MH, Peng X, Jeanfavre S, Clish C, et al
    Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.30308.
    >> Share

  17. FIUME S, Molinari F, Vai B, Poletti S, et al
    Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30321.
    >> Share

  18. FERRANTE FJ, Escobar Grisales D, Lopez MF, Lopes da Cunha P, et al
    Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.70005.
    >> Share

  19. CLARKE N, Thornton P, Reader V, Lindsay N, et al
    Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30307.
    >> Share

  20. KRAUSS J, Upadhyay N, Purrer V, Borger V, et al
    Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German Cohort.
    Mov Disord. 2025 Aug 8. doi: 10.1002/mds.70003.
    >> Share

  21. ZARKALI A, Thomas G, Paterson R, Hannaway N, et al
    Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease.
    Mov Disord. 2025 Aug 7. doi: 10.1002/mds.30325.
    >> Share

  22. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
    Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025;40:1604-1617.
    >> Share

  23. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    >> Share

  24. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    >> Share

    July 2025
  25. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.
    Mov Disord. 2025 Jul 31. doi: 10.1002/mds.30310.
    >> Share

  26. PRATUSEVICIUTE N, Lis P, Weber S, Gruchy N, et al
    Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.
    Mov Disord. 2025 Jul 30. doi: 10.1002/mds.30284.
    >> Share

  27. MATTIA GM, Chougar L, Foubert-Samier A, Meissner WG, et al
    Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging: A Proof-of-Concept Study.
    Mov Disord. 2025 Jul 24. doi: 10.1002/mds.30300.
    >> Share

  28. ANGELINI L, van den Berg K, Dirkx M, Bologna M, et al
    Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease.
    Mov Disord. 2025 Jul 21. doi: 10.1002/mds.30299.
    >> Share

  29. VALLI A, Scheperjans F
    Subacute Painful Axonal Polyneuropathy Associated with Foslevodopa/Foscarbidopa Subcutaneous Infusion in Advanced Parkinson's Disease.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30297.
    >> Share

  30. SWINNEN BEKS, Hoy CW, Little SJ
    Towards Adaptive Deep Brain Stimulation for Non-Motor Symptoms in Parkinson's Disease?
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30212.
    >> Share

  31. BIUNDO R, Bezdicek O, Cammisuli DM, Cholerton B, et al
    Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30293.
    >> Share

  32. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Bilateral Effects of Unilateral Pallidothalamic Tractotomy Using Focused Ultrasound in Parkinson's Disease.
    Mov Disord. 2025 Jul 17. doi: 10.1002/mds.30281.
    >> Share

  33. WEINTRAUB D, Schoen I
    The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30295.
    >> Share

  34. CHEN PS, Liu YL, Chiang PT, Tsai HH, et al
    Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals.
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30290.
    >> Share

  35. DAI Y, Bi M, Jiao Q, Du X, et al
    Deciphering the Janus-Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis.
    Mov Disord. 2025 Jul 14. doi: 10.1002/mds.30294.
    >> Share

  36. KUNG PJ, Tsai YT, Yu RL, Lin-Wang HH, et al
    Elevated Levels of Extracellular Vesicle-Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease.
    Mov Disord. 2025 Jul 11. doi: 10.1002/mds.30287.
    >> Share

  37. MOURADIAN MM, Stoessl AJ, Lang AE
    Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.
    Mov Disord. 2025 Jul 10. doi: 10.1002/mds.30259.
    >> Share

  38. OOI JCE, Tay YW, Tan AH, Lin CH, et al
    Evaluation of a Mitochondrial Polygenic Score for Parkinson's Disease Across Ancestries.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30285.
    >> Share

  39. REIS CARNEIRO D, Morgadinho A, Araujo R
    The Emergence of a New Healthcare Paradigm for People with Parkinson's Disease in Portugal: Brief Notes on Public and Private Healthcare Systems.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30292.
    >> Share

  40. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    Unraveling the Gut-Heart Axis: Missing Links in the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30268.
    >> Share

  41. BORGHAMMER P, Van Den Berge N, Skjaerbaek C, Horsager J, et al
    Trusting Your Gut When it Comes to the Origin of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30288.
    >> Share

  42. XU X, Guo Y, Xiong Y, Min Z, et al
    Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30289.
    >> Share

  43. BOURQUE M, Morissette M, Bortolato M, Frau R, et al
    Pregnenolone Reduces L-Dopa-Induced Dyskinesias in Female Parkinsonian Monkeys.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30280.
    >> Share

  44. LI C, Ou R, Hou Y, Wei Q, et al
    Validation of Genome-Wide Association Study (GWAS)-Identified Risk Loci for Parkinson's Disease in the Chinese Population.
    Mov Disord. 2025 Jul 3. doi: 10.1002/mds.30291.
    >> Share

  45. LI C, Ou R, Hou Y, Wei Q, et al
    GBA1 Haplotypes and Age at Onset of Parkinson's Disease in the Asian Population.
    Mov Disord. 2025 Jul 2. doi: 10.1002/mds.30283.
    >> Share

  46. SIMUNI T, Gochanour C, Nair AR, Brumm MC, et al
    Neuronal alpha-Synuclein Disease Stage Progression over 5 Years.
    Mov Disord. 2025;40:1318-1330.
    >> Share

  47. GONZALEZ-ROBLES C, Athauda D, Barber TR, Barker RA, et al
    Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
    Mov Disord. 2025;40:1307-1317.
    >> Share

  48. KAWABATA K, Krismer F, Ito M, Hara K, et al
    Trajectories of Pontine Volume in Patients with Multiple System Atrophy.
    Mov Disord. 2025;40:1369-1378.
    >> Share

  49. MIMMI S, Parrotta EI, Tolomeo AM, Maisano D, et al
    Neuronally-Derived Extracellular Vesicles Transforming Growth Factor Beta-1 Levels in Progressive Supranuclear Palsy.
    Mov Disord. 2025;40:1420-1426.
    >> Share

    June 2025
  50. ANJUM T, Raethjen J, Ding H, Koirala N, et al
    Central Pathophysiology and Brain Network Changes Related to Camptocormia in Parkinson's Disease.
    Mov Disord. 2025 Jun 29. doi: 10.1002/mds.30278.
    >> Share

  51. ESPAY AJ, Cardoso F, Frucht SJ, Imarisio A, et al
    Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS]).
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30269.
    >> Share

  52. SIMUNI T, Chahine LM, Poston KL, Kopil CM, et al
    Reply to: "Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS])".
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30272.
    >> Share

  53. HERTZ E, Rytel K, Perez G, Hao Y, et al
    Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2025 Jun 26. doi: 10.1002/mds.30273.
    >> Share

  54. HUH YE, Jang B, Jung SH, Kim D, et al
    Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi-Cohort Study.
    Mov Disord. 2025 Jun 25. doi: 10.1002/mds.30276.
    >> Share

  55. PASCHEN S, Natera-Villalba E, Rodriguez-Rojas R, Del Alamo M, et al
    Lesioning the Subthalamic Nucleus Using Magnetic Resonance Imaging-Guided Focused Ultrasound in Parkinson's Disease: Subthalamotomy Effectively Describes the Procedure.
    Mov Disord. 2025 Jun 23. doi: 10.1002/mds.30271.
    >> Share

  56. ZHANG G, Guan L, Gao Y, Shi L, et al
    Sleep Stage Classification Using Subthalamic Nucleus Local Field Potentials Following Long-Term Neuromodulation in Parkinson's Disease.
    Mov Disord. 2025 Jun 12. doi: 10.1002/mds.30264.
    >> Share

  57. RICCIARDI L, Cucinotta F, Pegolo E, Abundes-Corona A, et al
    Low/High Multi-Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease.
    Mov Disord. 2025 Jun 11. doi: 10.1002/mds.30254.
    >> Share

  58. MULLER T, Kuhn W
    Is Hypomethylation of the alpha-Synuclein Gene in Parkinson's Disease Patients Related to Chronic Levodopa Intake?
    Mov Disord. 2025 Jun 9. doi: 10.1002/mds.30263.
    >> Share

  59. ERRO R, Sorrentino C, Barone P
    Plastamination: A Rising Concern for Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30253.
    >> Share

  60. LIAO Y, Wu H, Wang J, Corvol JC, et al
    Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30252.
    >> Share

  61. ANANDAPADMANABHAN R, Vishnoi A, Raman G, Thachan J, et al
    Deep Learning-Based Artificial Intelligence Algorithm to Classify Tremors from Hand-Drawn Spirals.
    Mov Disord. 2025;40:1172-1181.
    >> Share

    May 2025
  62. GROS P, Marras C, Wang X, Chiu M, et al
    Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30239.
    >> Share

  63. DHAWAN V, Peng S, Spetsieris PG, Eidelberg D, et al
    Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30231.
    >> Share

  64. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Reply to: "Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example".
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30247.
    >> Share

  65. GONZALEZ DA, Karstens AJ, Patel SES, Fleisher JE, et al
    The Parkinson's Disease Cognitive Composite: Lessons Forgotten from Preclinical Alzheimer's Cognitive Composites.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30246.
    >> Share

  66. FERESHTEHNEJAD SM, Moqadam R, Azizi H, Postuma RB, et al
    Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight toward Precision Medicine.
    Mov Disord. 2025 May 26. doi: 10.1002/mds.30229.
    >> Share

  67. WALSHE M, Hirschwald J, Warnecke T
    Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30241.
    >> Share

  68. VAZIRIAN F, Tian J, Cicuttini F, Jones G, et al
    Reply to: "Chronic Pain and Parkinson's Disease: Causation or Confounding?".
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30234.
    >> Share

  69. XU QH, Wang YL, Zhang BR, Tian J, et al
    Chronic Pain and Parkinson's Disease: Causation or Confounding?
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30235.
    >> Share

  70. AAMODT WW, Eickholt L, Coughlin DG, Solomon L, et al
    Sex and Racial/Ethnic Differences in End-of-Life Care Preferences in Persons with Parkinson's Disease and Related Disorders.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30240.
    >> Share

  71. VAN LAAR AD, Christine CW, Phielipp N, Larson PS, et al
    Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.
    Mov Disord. 2025 May 20. doi: 10.1002/mds.30193.
    >> Share

  72. GAN-OR Z, Alcalay RN
    LRRK2-Associated Parkinson's Disease: Is it a Synucleinopathy After All?
    Mov Disord. 2025 May 19. doi: 10.1002/mds.30228.
    >> Share

  73. AFAAR F, Youssef P, Galper J, Chua M, et al
    Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease.
    Mov Disord. 2025 May 16. doi: 10.1002/mds.30233.
    >> Share

  74. PONS R, Pearson TS, Perez-Duenas B, Garcia-Cazorla A, et al
    Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.
    Mov Disord. 2025 May 13. doi: 10.1002/mds.30219.
    >> Share

  75. SUPPA A, Asci F, Kamble N, Chen KH, et al
    Neurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper.
    Mov Disord. 2025 May 12. doi: 10.1002/mds.30225.
    >> Share

  76. STRANIERO L, Rimoldi V, Cereda E, Solda G, et al
    Genetics Influences Telomere Length in Parkinson's Disease: A Study in Monozygotic Discordant Twins.
    Mov Disord. 2025 May 9. doi: 10.1002/mds.30224.
    >> Share

  77. YUCEL M, Odorfer T, Volkmann J, Zeller D, et al
    Revisiting Coactivation ("Froment's Maneuver") in Parkinson's Disease: A Physiological Approach.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30226.
    >> Share

  78. IMBALZANO G, Montanaro E, Ledda C, Donetto F, et al
    Theta-Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30218.
    >> Share

    April 2025
  79. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Are there Predictors for the Effects of Subthalamic Versus Thalamic Lesions for the Treatment of Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30216.
    >> Share

  80. AUBIGNAT M
    Does Dopamine Sensitivity Influence the Choice between Subthalamotomy and Thalamotomy for Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30215.
    >> Share

  81. DI VICO IA, Moretto M, Tamanti A, Tomelleri G, et al
    Molecular-Informed Network Analysis Unveils Fatigue-Related Functional Connectivity in Parkinson's Disease.
    Mov Disord. 2025 Apr 22. doi: 10.1002/mds.30214.
    >> Share

  82. WEINTRAUB D, Chaudhuri KR, Schrag A, Martinez-Martin P, et al
    Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q).
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30202.
    >> Share

  83. WIESMAN AI, Vinding MC, Tsitsi P, Svenningsson P, et al
    Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease.
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30200.
    >> Share

  84. SMITH MD, Portlock GE, Cullen A, Nodehi A, et al
    Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).
    Mov Disord. 2025 Apr 17. doi: 10.1002/mds.30186.
    >> Share

  85. CHOU KL, Kanel P, van Emde Boas M, Roytman S, et al
    Cholinergic System Changes in Dopa-Unresponsive Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Apr 11. doi: 10.1002/mds.30196.
    >> Share

  86. LAMOS M, Bockova M, Missey F, Lubrano C, et al
    Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity.
    Mov Disord. 2025 Apr 9. doi: 10.1002/mds.30134.
    >> Share

  87. SCHOENWALD H, Bahners BH, Kannenberg S, Dembek TA, et al
    Antero-Lateral Subthalamic Nucleus Theta Stimulation Improves Verbal Fluency in Parkinson's Disease.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30185.
    >> Share

  88. CARRA RB, Garcia LAL, Menezes JR, Capato T, et al
    Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double-Blinded Evaluation.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30187.
    >> Share

  89. AMMANN C, Pagge C, Wilhelm E, Galletti C, et al
    Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease.
    Mov Disord. 2025 Apr 1. doi: 10.1002/mds.30171.
    >> Share

  90. LIU H, Zhu Q, Wang J, Qin C, et al
    Assessment of Piezo1 Expression in Urinary Exfoliated Cells as a Diagnostic Indicator for Multiple System Atrophy.
    Mov Disord. 2025;40:759-764.
    >> Share

  91. ROSSI M, Schaake S, Usnich T, Boehm J, et al
    Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.
    Mov Disord. 2025;40:605-618.
    >> Share

  92. TRUJILLO P, O'Rourke KR, Roman OC, Song AK, et al
    Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin-Sensitive Magnetic Resonance Imaging and (18)F-Fluorodopa-Positron Emission Tomography.
    Mov Disord. 2025;40:716-726.
    >> Share

    March 2025
  93. BEZDICEK O, Biundo R, Boelema S, Cammisuli DM, et al
    Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Mar 27. doi: 10.1002/mds.30166.
    >> Share

  94. GARON M, Rojo-Albuin JM, Chaudhuri KR, Rizos A, et al
    Conversion between NMSS and MDS-NMS in Parkinson's Disease.
    Mov Disord. 2025 Mar 20. doi: 10.1002/mds.30172.
    >> Share

  95. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    The Heart of the Matter: Cardiac Denervation Casts Doubt on the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30174.
    >> Share

  96. MESTRE TA, Sampaio C
    Is Parkinson Disease Better Defined Solely by Biology or as a Clinical-Biological Entity? Lessons to be Learned from Alzheimer's Disease on Biological Definition and Staging.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30173.
    >> Share

  97. YAN R, Zheng X, Yin Y, Zhang J, et al
    Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30179.
    >> Share

  98. BEHNKE JK, Peach RL, Habets JGV, Busch JL, et al
    Long-Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30169.
    >> Share

  99. SVENNINGSSON P, Odin P, Bergquist F, Wirdefeldt K, et al
    NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.
    Mov Disord. 2025 Mar 17. doi: 10.1002/mds.30175.
    >> Share

  100. WILPERT NM, Hewitt AL, Pons R, Henke MT, et al
    Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.
    Mov Disord. 2025 Mar 15. doi: 10.1002/mds.30152.
    >> Share

  101. COLOMBO A, Bernasconi E, Alva L, Sousa M, et al
    Finely Tuned gamma Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.
    Mov Disord. 2025 Mar 13. doi: 10.1002/mds.30160.
    >> Share

  102. DE BIE RMA, Katzenschlager R, Swinnen BEKS, Peball M, et al
    Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2025 Mar 8. doi: 10.1002/mds.30162.
    >> Share

  103. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.
    Mov Disord. 2025 Mar 3. doi: 10.1002/mds.30159.
    >> Share

    February 2025
  104. YAO P, Sharma A, Abdi-Sargezeh B, Liu T, et al
    Beta Burst Characteristics and Coupling within the Sensorimotor Cortical-Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease.
    Mov Disord. 2025 Feb 27. doi: 10.1002/mds.30163.
    >> Share

  105. SU D, Ji L, Cui Y, Gan L, et al
    Altered Visuomotor Network Dynamics Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Feb 25. doi: 10.1002/mds.30146.
    >> Share

  106. NI Y, Yin YN, Yu WB, Liu YQ, et al
    Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.
    Mov Disord. 2025 Feb 19. doi: 10.1002/mds.30154.
    >> Share

  107. SONG S, Luo Z, Plassman BL, Huang X, et al
    Self-Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers.
    Mov Disord. 2025 Feb 14. doi: 10.1002/mds.30149.
    >> Share

  108. SUN S, Madge V, Djordjevic J, Gagnon JF, et al
    Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.
    Mov Disord. 2025 Feb 13. doi: 10.1002/mds.30148.
    >> Share

  109. WALLIN J, Forsberg A, Svenningsson P
    Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [(11)C]PBR28 PET.
    Mov Disord. 2025 Feb 6. doi: 10.1002/mds.30144.
    >> Share

  110. SANTOS-LOBATO BL
    New Insights into the Association of Pesticide Exposure and Parkinson's Disease.
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30135.
    >> Share

  111. JANSSEN DAALEN J, van der Heiden M, Meinders M, Post B, et al
    Motor Symptom Variability in Parkinson's Disease: Implications for Personalized Trial Outcomes?
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30133.
    >> Share

  112. WU Y, Xu W
    Addressing Methodological Variability and Enhancing Efficacy Assessment in Focused Ultrasound Thalamotomy for Parkinson's Tremor.
    Mov Disord. 2025 Feb 4. doi: 10.1002/mds.30136.
    >> Share

  113. LO RY
    To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson's Disease.
    Mov Disord. 2025;40:181-183.
    >> Share

  114. WIEST C, Simpson TG, Pogosyan A, Hasegawa H, et al
    Stimulation-Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep.
    Mov Disord. 2025;40:351-356.
    >> Share

    January 2025
  115. GIBBON S, Breen DP, MacGillivray TJ
    Optic Disc Pallor in Parkinson's Disease: A UK Biobank Study.
    Mov Disord. 2025 Jan 30. doi: 10.1002/mds.30127.
    >> Share

  116. TOODAYAN N, Lees AJ
    Two London Memorials to "James Parkinson [1755-1824], Esq. Surgeon, Late of Hoxton-Square".
    Mov Disord. 2025 Jan 24. doi: 10.1002/mds.30115.
    >> Share

  117. FU Y, Adler GL, Youssef P, Phan K, et al
    Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease.
    Mov Disord. 2025 Jan 22. doi: 10.1002/mds.30128.
    >> Share

  118. BRACCIA A, Golfre Andreasi N, Ghielmetti F, Aquino D, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse.
    Mov Disord. 2025 Jan 18. doi: 10.1002/mds.30093.
    >> Share

  119. LIANG M, Chu L, Yue Z
    New Multiomic Studies Shed Light on Cellular Diversity and Neuronal Susceptibility in Parkinson's Disease.
    Mov Disord. 2025 Jan 15. doi: 10.1002/mds.30097.
    >> Share

  120. FALLETTI M, Asci F, Zampogna A, Patera M, et al
    Rigidity in Parkinson's Disease: The Objective Effect of Levodopa.
    Mov Disord. 2025 Jan 8. doi: 10.1002/mds.30114.
    >> Share

  121. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30111.
    >> Share

  122. JO S, Oh JH, Lee EJ, Choi M, et al
    Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30098.
    >> Share

  123. GUSTAVSSON EK
    Editorial on: Confirmation of RAB32 Ser71Arg involvement in Parkinson's disease.
    Mov Disord. 2025;40:5-6.
    >> Share

    December 2024
  124. TSAI SY, Tai CH, Lee YY
    Use of Transcranial Magnetic Stimulation to Probe Neuroplasticity and Predict Gait Performance After Treadmill Training in Parkinson's Disease.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30100.
    >> Share

  125. MAGISTRELLI L, Brumana M, Rimoldi V, Poggi-Longostrevi S, et al
    The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30103.
    >> Share

  126. RODRIGUEZ-OROZ MC, Martinez-Fernandez R, Lipsman N, Horisawa S, et al
    Bilateral Lesions in Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2024 Dec 27. doi: 10.1002/mds.30090.
    >> Share

  127. DE MENA L, Pares G, Garrido A, Pilco-Janeta DF, et al
    alpha-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.
    Mov Disord. 2024 Dec 23. doi: 10.1002/mds.30094.
    >> Share

  128. GUAN L, Yu H, Chen Y, Gong C, et al
    Subthalamic gamma Oscillation Underlying Rapid Eye Movement Sleep Abnormality in Parkinsonian Patients.
    Mov Disord. 2024 Dec 20. doi: 10.1002/mds.30091.
    >> Share

  129. GRILLO P, Concha-Marambio L, Pisani A, Riboldi GM, et al
    Association between the Amplification Parameters of the alpha-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Dec 18. doi: 10.1002/mds.30085.
    >> Share

  130. VAN DEN BERG KRE, Johansson ME, Dirkx MF, Bloem BR, et al
    Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.
    Mov Disord. 2024 Dec 16. doi: 10.1002/mds.30081.
    >> Share

  131. LEE CH, Juan CH, Chen HH, Hong JP, et al
    Long-Range Temporal Correlations in Electroencephalography for Parkinson's Disease Progression.
    Mov Disord. 2024 Dec 11. doi: 10.1002/mds.30074.
    >> Share

  132. CERNERA S, Oehrn CR, Hammer LH, Shcherbakova M, et al
    Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30076.
    >> Share

  133. GOLDMAN SM, Weaver FM, Cao L, Gonzalez B, et al
    Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30075.
    >> Share

  134. WOO KA, Yoon EJ, Kim S, Kim H, et al
    Cognitive Impact of beta-Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder-Lewy Body Disease Continuum.
    Mov Disord. 2024;39:2259-2270.
    >> Share

    November 2024
  135. RABANO-SUAREZ P, Del Campo N, Benatru I, Moreau C, et al
    Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30056.
    >> Share

  136. CONTI M, D'Onofrio V, Bovenzi R, Ferrari V, et al
    Cortical Functional Connectivity Changes in the Body-First and Brain-First Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30071.
    >> Share

  137. ATTERLING BROLIN K, Schaeffer E, Kuri A, Rumrich IK, et al
    Environmental Risk Factors for Parkinson's Disease: A Critical Review and Policy Implications.
    Mov Disord. 2024 Nov 27. doi: 10.1002/mds.30067.
    >> Share

  138. HERZ DM, Blech J, Winter Y, Gonzalez-Escamilla G, et al
    Low-Frequency Deep Brain Stimulation in Non-Rapid Eye Movement Sleep Modifies Memory Retention in Parkinson's Disease.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30064.
    >> Share

  139. WANG S, Ou R, Huang J, Lin J, et al
    RAB32 Variants in a Chinese Parkinson's Disease Cohort.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30065.
    >> Share

  140. KOSZYCKI D, Taljaard M, Bradwejn J, Lee C, et al
    Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial.
    Mov Disord. 2024 Nov 20. doi: 10.1002/mds.30061.
    >> Share

  141. ZHAO Y, Lai Y, Darweesh SKL, Bloem BR, et al
    Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study.
    Mov Disord. 2024 Nov 12. doi: 10.1002/mds.30054.
    >> Share

  142. HWANG YS, Jo S, Lee SH, Park KW, et al
    Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome-wide Association Study.
    Mov Disord. 2024 Nov 6. doi: 10.1002/mds.30047.
    >> Share

  143. ZAGARE A, Hemedan A, Almeida C, Frangenberg D, et al
    Insulin Resistance Is a Modifying Factor for Parkinson's Disease.
    Mov Disord. 2024 Nov 5. doi: 10.1002/mds.30039.
    >> Share

  144. VAZIRIAN F, Tian J, Jane Alty, Aitken D, et al
    Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study.
    Mov Disord. 2024 Nov 2. doi: 10.1002/mds.30046.
    >> Share

  145. BALACHANDAR A, Hashim Y, Vaou O, Fasano A, et al
    Automated Sleep Detection in Movement Disorders Using Deep Brain Stimulation and Machine Learning.
    Mov Disord. 2024;39:2097-2102.
    >> Share

  146. LOPICCOLO MK, Wang Z, Eshed GM, Fierro L, et al
    Skin alpha-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.
    Mov Disord. 2024;39:2087-2091.
    >> Share

    October 2024
  147. CAO S, Fang X, Wang J, Sun Y, et al
    Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients of Bullous Pemphigoid with or without Parkinson's Disease.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30045.
    >> Share

  148. STEP K, Eltaraifee E, Elsayed I, Rasaholiarison N, et al
    Advancing Parkinson's Disease Research in Africa: A Strategic Training Framework of the Global Parkinson's Genetics Program.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30051.
    >> Share

  149. RADEFELDT M, Lemke S, Chaichoompu K, Paul JJ, et al
    Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease.
    Mov Disord. 2024 Oct 26. doi: 10.1002/mds.30041.
    >> Share

  150. MAHAJAN A, Morrow CB, Seemiller J, Mills KA, et al
    The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson's Disease.
    Mov Disord. 2024 Oct 25. doi: 10.1002/mds.30044.
    >> Share

  151. EMMI A, Macchi V, Stocco E, Tushevski A, et al
    alpha-Synuclein Pathology in the Carotid Body: Experimental Evidence for a possible Contributor to Respiratory Impairment in Parkinson's Disease.
    Mov Disord. 2024 Oct 24. doi: 10.1002/mds.30036.
    >> Share

  152. AJALIN R, Al-Abdulrasul H, Tuisku JM, Hirvonen J, et al
    Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.
    Mov Disord. 2024 Oct 22. doi: 10.1002/mds.30042.
    >> Share

  153. HINES K, Noecker AM, Frankemolle-Gilbert AM, Liang TW, et al
    Prospective Connectomic-Based Deep Brain Stimulation Programming for Parkinson's Disease.
    Mov Disord. 2024 Oct 21. doi: 10.1002/mds.30026.
    >> Share

  154. SLATER NM, Melzer TR, Myall DJ, Anderson TJ, et al
    Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence.
    Mov Disord. 2024 Oct 3. doi: 10.1002/mds.30023.
    >> Share

  155. CHURCHILL L, Chen YC, Lewis SJG, Matar E, et al
    Understanding REM Sleep Behavior Disorder through Functional MRI: A Systematic Review.
    Mov Disord. 2024;39:1679-1696.
    >> Share

  156. KHOSOUSI S, Sturchio A, Appleton E, Paslawski W, et al
    Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
    Mov Disord. 2024;39:1881-1885.
    >> Share

    September 2024
  157. COGAN G, Tesson C, Brefel-Courbon C, Lanore A, et al
    Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease.
    Mov Disord. 2024 Sep 23. doi: 10.1002/mds.30024.
    >> Share

  158. GABBERT C, Shambetova C, Much C, Trinh J, et al
    RAB32 Variants in a German Parkinson's Disease Cohort.
    Mov Disord. 2024 Sep 19. doi: 10.1002/mds.30005.
    >> Share

  159. ARMENGOU-GARCIA L, Sanchez-Catasus CA, Aviles-Olmos I, Jimenez-Huete A, et al
    Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.30020.
    >> Share

  160. TANIGUCHI S, Kajiyama Y, Kochiyama T, Revankar G, et al
    New Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.29988.
    >> Share

  161. VIEIRA SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, et al
    Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
    Mov Disord. 2024 Sep 11. doi: 10.1002/mds.30006.
    >> Share

  162. KALIA LV, Berg D, Kordower JH, Shannon KM, et al
    Movement Disorders Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions.
    Mov Disord. 2024 Sep 9. doi: 10.1002/mds.30007.
    >> Share

  163. DZIALAS V, Doering E, Eich H, Strafella AP, et al
    Houston, We Have AI Problem! Quality Issues with Neuroimaging-Based Artificial Intelligence in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Sep 5. doi: 10.1002/mds.30002.
    >> Share

  164. NIEMI KJ, Sunikka J, Soltanian-Zadeh H, Davoodi-Bojd E, et al
    Rest Tremor in Parkinson's Disease Is Associated with Ipsilateral Striatal Dopamine Transporter Binding.
    Mov Disord. 2024 Sep 3. doi: 10.1002/mds.29997.
    >> Share

  165. WIJERS A, Ravi A, Evers SMAA, Tissingh G, et al
    Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective.
    Mov Disord. 2024 Sep 2. doi: 10.1002/mds.29995.
    >> Share


  166. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S809-S858.
    >> Share


  167. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S199-S213.
    >> Share


  168. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S593-S739.
    >> Share


  169. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S290-S353.
    >> Share


  170. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S435-S592.
    >> Share


  171. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S241-S289.
    >> Share


  172. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S740-S808.
    >> Share


  173. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S214-S240.
    >> Share


  174. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S859-S896.
    >> Share


  175. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S1-S99.
    >> Share


  176. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S100-S198.
    >> Share


  177. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S354-S434.
    >> Share

    August 2024
  178. METCALFE-ROACH A, Cirstea MS, Yu AC, Ramay HR, et al
    Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2024 Aug 28. doi: 10.1002/mds.29959.
    >> Share

  179. TANG H, Lu Y, Okun MS, Donahoo WT, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Mov Disord. 2024 Aug 27. doi: 10.1002/mds.29992.
    >> Share

  180. GUIDA P, Martinez-Fernandez R, Manez-Miro JU, Del Alamo M, et al
    Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study.
    Mov Disord. 2024 Aug 14. doi: 10.1002/mds.29945.
    >> Share

  181. LAZARO-FIGUEROA A, Hernandez-Medrano AJ, Ramirez-Pineda DB, Navarro Cadavid A, et al
    Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29719.
    >> Share

  182. YANG C, Xu Y, Feng X, Wang B, et al
    Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29967.
    >> Share

  183. SOSERO YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, et al
    Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29960.
    >> Share

  184. CHEYUO C, Germann J, Yamamoto K, Zibly Z, et al
    Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29965.
    >> Share

  185. MATAR E, Tinazzi M, Edwards MJ, Bhatia KP, et al
    Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease-Clinical and Pathophysiological Insights.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29958.
    >> Share

  186. KIKUYA A, Tsukita K, Sawamura M, Yoshimura K, et al
    Distinct Clinical Implications of Patient- Versus Clinician-Rated Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2024 Aug 2. doi: 10.1002/mds.29962.
    >> Share

  187. TIAN Q, Ding J
    Advancing Parkinson's Research through Psychological Assessments of Deep Brain Stimulation Effects.
    Mov Disord. 2024;39:1429-1430.
    >> Share

  188. XIAO H, Lang L, Ye Z, Wu J, et al
    Advancing Parkinson's Research: Considerations and Future Directions.
    Mov Disord. 2024;39:1430-1431.
    >> Share

  189. SONG P, Krainc D
    Diverse Functions of Parkin in Midbrain Dopaminergic Neurons.
    Mov Disord. 2024;39:1282-1288.
    >> Share

  190. ZHENG Y, Yu Z, Cai H, Kou W, et al
    Detection of alpha-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1300-1309.
    >> Share

  191. AMRAMI A, Singh NA, Ali F, Pham NTT, et al
    Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:1402-1407.
    >> Share

    July 2024
  192. VIRAMETEEKUL S, Lees AJ, Bhidayasiri R
    Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29939.
    >> Share

  193. JUNKER J, Lange LM, Vollstedt EJ, Roopnarain K, et al
    Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29925.
    >> Share

  194. BELLINI G, Rettura F, Palermo G, Ippolito C, et al
    Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29937.
    >> Share

  195. GOEDE LL, Oxenford S, Kroneberg D, Meyer GM, et al
    Linking Invasive and Noninvasive Brain Stimulation in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29940.
    >> Share

  196. LORENZO-BETANCOR O, Mehta S, Ramchandra J, Mumuney S, et al
    Parkinson's Disease Gene Screening in Familial Cases from Central and South America.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29931.
    >> Share

  197. GIBSON LL, Weintraub D, Lemmen R, Perera G, et al
    Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jul 22. doi: 10.1002/mds.29918.
    >> Share

  198. KARIV S, Choi JW, Mirpour K, Gordon AM, et al
    Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease.
    Mov Disord. 2024 Jul 15. doi: 10.1002/mds.29928.
    >> Share

  199. ILLNER V, Novotny M, Kouba T, Tykalova T, et al
    Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Jul 12. doi: 10.1002/mds.29921.
    >> Share

  200. BERNHARDT AM, Nemati M, Boros FA, Hopfner F, et al
    alpha-Synuclein Seed Amplification Assays from Blood-Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29923.
    >> Share

  201. WOOD KH, Nenert R, Miften AM, Kent GW, et al
    Diffusion Tensor Imaging-Along the Perivascular-Space Index Is Associated with Disease Progression in Parkinson's Disease.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29908.
    >> Share

  202. GOLDMAN SM, Weaver FM, Gonzalez B, Stroupe KT, et al
    Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29922.
    >> Share

  203. MUSTILE M, Kourtis D, Ladouce S, Edwards MG, et al
    Investigating the Brain Mechanisms of Externally Cued Sit-to-Stand Movement in Parkinson's Disease.
    Mov Disord. 2024 Jul 10. doi: 10.1002/mds.29889.
    >> Share

  204. DE JESUS S, Daya A, Blumberger L, Lewis MM, et al
    Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29900.
    >> Share

  205. BALTA BEYLERGIL S, Skelly P, Quagraine I, Kilbane C, et al
    Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29907.
    >> Share

  206. GUO S, Yang G
    Integrating Social Work in Late-Stage Parkinson's Care: A Multifaceted Approach.
    Mov Disord. 2024;39:1249-1250.
    >> Share

  207. KRUSE C, Dodel R, Schrag A
    Reply to Letter to the Editor-MDS-23-0498.R2/MDS-24-0318.R1.
    Mov Disord. 2024;39:1251-1252.
    >> Share

  208. ADLER CH, Halverson M, Zhang N, Shill HA, et al
    Conjugal Synucleinopathies: A Clinicopathologic Study.
    Mov Disord. 2024;39:1212-1217.
    >> Share

  209. ZHENG Y, Li Y, Cai H, Kou W, et al
    Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024;39:1179-1189.
    >> Share

    June 2024
  210. BURRE J, Edwards RH, Halliday G, Lang AE, et al
    Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis.
    Mov Disord. 2024 Jun 30. doi: 10.1002/mds.29897.
    >> Share

  211. AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
    Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
    >> Share

  212. COGAN G, Daida K, Billingsley KJ, Tesson C, et al
    Long-Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early-Onset Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29914.
    >> Share

  213. FABBRI M, Rascol O, Foltynie T, Carroll C, et al
    Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
    Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
    >> Share

  214. LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
    Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
    Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
    >> Share

  215. WANG X, Fu S, Yoo K, Wang X, et al
    Individualized Structural Perturbations on Normative Brain Connectome Restrict Deep Brain Stimulation Outcomes in Parkinson's Disease.
    Mov Disord. 2024 Jun 18. doi: 10.1002/mds.29874.
    >> Share

  216. KIMURA Y, Mochizuki H
    Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.
    Mov Disord. 2024 Jun 14. doi: 10.1002/mds.29884.
    >> Share

  217. BREFEL-COURBON C, Harroch E, Marques A, Devos D, et al
    Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
    Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
    >> Share

  218. JENSEN I, Heine J, Ruf VC, Compta Y, et al
    Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
    Mov Disord. 2024 Jun 7. doi: 10.1002/mds.29879.
    >> Share

  219. KORCZYN AD
    Rethinking Parkinson's Disease: A Syndromic Perspective.
    Mov Disord. 2024;39:1079-1080.
    >> Share

  220. LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
    The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
    Mov Disord. 2024;39:1084.
    >> Share

  221. OUTEIRO TF, Antonini A, Ferreira JJ
    Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
    Mov Disord. 2024;39:1080-1081.
    >> Share

  222. SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
    Defining the Importance of Minor Hallucinations in Parkinson's Disease.
    Mov Disord. 2024;39:1083.
    >> Share

  223. OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
    Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
    Mov Disord. 2024;39:945-954.
    >> Share

  224. BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
    Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
    Mov Disord. 2024;39:936-944.
    >> Share

  225. SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
    The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1054-1059.
    >> Share

  226. AVENALI M, Cerri S, Palmieri I, Ongari G, et al
    Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
    Mov Disord. 2024;39:1060-1065.
    >> Share

    May 2024
  227. GRIPPE T, Shamli-Oghli Y, Darmani G, Nankoo JF, et al
    Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease.
    Mov Disord. 2024 May 24. doi: 10.1002/mds.29836.
    >> Share

  228. VAN MIDDEN V, Simoncic U, Pirtosek Z, Kojovic M, et al
    The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study.
    Mov Disord. 2024 May 17. doi: 10.1002/mds.29826.
    >> Share

  229. ZHANG J, Liu Y, Zhao C
    SNCA-Related Parkinson's Disease Caused by Complete Chromosome 4 Paternal Uniparental Disomy.
    Mov Disord. 2024 May 13. doi: 10.1002/mds.29823.
    >> Share

  230. HEISS JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, et al
    Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
    Mov Disord. 2024 May 8. doi: 10.1002/mds.29820.
    >> Share

  231. XIAO H, Lang L, Ye Z, Wu J, et al
    Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease.
    Mov Disord. 2024 May 2. doi: 10.1002/mds.29830.
    >> Share

  232. MA JH, Dong C, Qiao HW, Barret O, et al
    Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:847-854.
    >> Share

    April 2024
  233. DODET P, Houot M, Leu-Semenescu S, Gaurav R, et al
    Isolated REM Sleep without Atonia Is Not Equivalent to REM Sleep Behavior Disorder in Early-Stage Parkinson's Disease.
    Mov Disord. 2024 Apr 26. doi: 10.1002/mds.29813.
    >> Share

  234. MONCHI O, Pinilla-Monsalve GD, Almgren H, Ghahremani M, et al
    White Matter Microstructural Underpinnings of Mild Behavioral Impairment in Parkinson's Disease.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29804.
    >> Share

  235. SENKEVICH K, Miliukhina I, Zhuravlev A, Shumilova M, et al
    Autosomal Dominant Parkinson's Disease Caused by SNCA p.E46K Mutation in a Family with Russian Ancestry.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29821.
    >> Share

  236. KLUGE A, Schaeffer E, Bunk J, Sommerauer M, et al
    Detecting Misfolded alpha-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.
    Mov Disord. 2024 Apr 23. doi: 10.1002/mds.29766.
    >> Share

  237. FREQUIN HL, Verschuur CVM, Suwijn SR, Boel JA, et al
    Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Mov Disord. 2024 Apr 21. doi: 10.1002/mds.29796.
    >> Share

  238. WANG Y, Li H, Song N, Xie J, et al
    Yeast Prion Protein Sup35 Initiates alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2024 Apr 16. doi: 10.1002/mds.29810.
    >> Share

  239. LASS J, Luth T, Schluter K, Schaake S, et al
    Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2024 Apr 14. doi: 10.1002/mds.29809.
    >> Share

  240. SHARMA K, Kishore A, Lechado-Terradas A, Passannanti R, et al
    A Novel PINK1 p.F385S Loss-of-Function Mutation in an Indian Family with Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29792.
    >> Share

  241. NIEMI KJ, Huovinen A, Jaakkola E, Glerean E, et al
    Bodily Maps of Symptoms and Emotions in Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29785.
    >> Share

  242. DU J, Zhang P, Tan Y, Gao C, et al
    Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
    Mov Disord. 2024 Apr 1. doi: 10.1002/mds.29803.
    >> Share

  243. ONDER H
    Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:758-759.
    >> Share

  244. PETERS J, Maamary J, Kyle K, Olsen N, et al
    Reply to: Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:759-760.
    >> Share

  245. BOOGERS A, Fasano A
    Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2024;39:761.
    >> Share

  246. XIE T, Warnke PC
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:760-761.
    >> Share

  247. PATEL J, Dawson VL, Dawson TM
    Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.
    Mov Disord. 2024;39:644-650.
    >> Share

  248. KORNILOV E, Baker Erdman H, Kahana E, Fireman S, et al
    Interleaved Propofol-Ketamine Maintains DBS Physiology and Hemodynamic Stability: A Double-Blind Randomized Controlled Trial.
    Mov Disord. 2024;39:694-705.
    >> Share

  249. STEINA A, Sure S, Butz M, Vesper J, et al
    Mapping Subcortico-Cortical Coupling-A Comparison of Thalamic and Subthalamic Oscillations.
    Mov Disord. 2024;39:684-693.
    >> Share

    March 2024

  250. Correction to "Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus".
    Mov Disord. 2024 Mar 29. doi: 10.1002/mds.29805.
    >> Share

  251. VERONESE N, Nova A, Fazia T, Riggi E, et al
    Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
    >> Share

  252. DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
    Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
    >> Share

  253. LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
    Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
    >> Share

  254. FRIEDMAN JH
    A New Definition of Psychosis Is Needed in Parkinson's Disease.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
    >> Share

  255. ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
    On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
    >> Share

  256. CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
    Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
    >> Share

  257. MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
    Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
    Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
    >> Share

  258. PARDO J, Montal V, Campabadal A, Oltra J, et al
    Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
    >> Share

  259. SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
    Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
    >> Share

  260. BINGHAM CS, McIntyre CC
    Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
    Mov Disord. 2024;39:539-545.
    >> Share

  261. LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
    Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    Mov Disord. 2024;39:613-618.
    >> Share

  262. THOMSEN M, Marth K, Loens S, Everding J, et al
    Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
    Mov Disord. 2024;39:526-538.
    >> Share

  263. MUNCHAU A, Klein C, Beste C
    Rethinking Movement Disorders.
    Mov Disord. 2024;39:472-484.
    >> Share

  264. KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
    Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
    Mov Disord. 2024;39:628-630.
    >> Share

    February 2024
  265. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    >> Share

  266. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    >> Share

  267. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    >> Share

  268. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    >> Share

  269. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    >> Share

  270. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    >> Share

  271. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    >> Share

  272. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    >> Share

  273. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    >> Share

  274. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    >> Share

    January 2024
  275. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    >> Share

  276. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    >> Share

  277. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    >> Share

  278. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    >> Share

  279. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    >> Share

  280. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    >> Share

  281. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    >> Share

  282. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    >> Share

  283. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    >> Share

  284. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    >> Share

  285. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    >> Share

  286. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    >> Share

  287. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    >> Share

  288. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    >> Share

  289. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    >> Share

  290. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    >> Share

  291. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    >> Share

  292. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    >> Share

  293. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    >> Share

    December 2023
  294. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    >> Share

  295. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    >> Share

  296. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    >> Share

  297. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    >> Share

  298. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    >> Share

  299. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    >> Share

  300. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    >> Share

  301. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    >> Share

  302. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    >> Share

  303. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    >> Share

  304. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    >> Share

  305. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    >> Share

  306. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    >> Share

  307. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    >> Share

  308. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    >> Share

  309. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    >> Share

    November 2023
  310. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    >> Share

  311. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    >> Share

  312. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    >> Share

  313. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    >> Share


  314. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    >> Share

  315. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    >> Share

  316. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    >> Share

  317. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    >> Share

  318. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    >> Share

  319. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    >> Share

  320. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    >> Share

  321. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    >> Share

  322. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    >> Share

  323. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    >> Share


  324. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    >> Share

  325. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    >> Share

  326. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    >> Share

  327. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    >> Share

    October 2023
  328. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    >> Share

  329. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    >> Share

  330. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    >> Share

  331. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    >> Share

  332. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    >> Share

  333. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    >> Share

  334. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    >> Share

  335. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    >> Share

  336. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    >> Share

  337. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    >> Share

  338. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    >> Share

  339. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    >> Share

    September 2023
  340. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    >> Share

  341. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    >> Share

  342. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    >> Share

  343. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    >> Share

  344. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    >> Share

  345. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    >> Share

  346. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    >> Share

  347. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    >> Share


  348. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    >> Share

  349. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    >> Share

  350. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    >> Share

  351. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    >> Share

  352. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    >> Share

    August 2023
  353. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    >> Share

  354. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    >> Share

  355. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    >> Share

  356. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    >> Share

  357. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    >> Share

  358. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    >> Share

  359. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    >> Share

  360. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    >> Share

  361. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    >> Share

  362. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    >> Share

  363. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    >> Share

  364. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    >> Share

  365. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    >> Share

  366. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    >> Share

  367. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    >> Share

  368. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    >> Share

  369. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    >> Share

  370. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    >> Share

  371. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    >> Share

  372. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    >> Share


  373. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    >> Share

  374. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    >> Share

    July 2023
  375. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    >> Share

  376. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    >> Share

  377. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    >> Share

  378. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    >> Share

  379. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    >> Share

  380. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    >> Share

  381. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    >> Share

  382. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    >> Share

  383. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    >> Share

  384. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    >> Share

  385. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    >> Share

  386. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    >> Share

    June 2023
  387. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    >> Share

  388. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    >> Share

  389. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    >> Share

  390. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    >> Share

  391. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    >> Share

  392. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    >> Share

  393. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    >> Share

  394. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    >> Share

  395. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    >> Share

  396. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    >> Share

  397. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    >> Share

  398. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    >> Share

  399. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    >> Share

  400. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    >> Share

  401. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    >> Share

  402. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    >> Share

  403. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    >> Share

  404. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    >> Share

  405. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    >> Share

  406. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    >> Share

  407. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    >> Share

  408. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    >> Share

  409. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    >> Share

  410. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    >> Share

  411. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    >> Share

    May 2023
  412. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    >> Share

  413. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    >> Share

  414. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    >> Share

  415. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    >> Share

  416. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    >> Share

  417. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    >> Share

  418. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    >> Share

  419. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    >> Share

  420. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    >> Share

  421. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    >> Share

  422. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    >> Share

  423. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    >> Share

  424. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    >> Share

  425. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    >> Share

  426. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    >> Share

  427. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    >> Share

  428. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    >> Share

  429. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    >> Share

  430. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    >> Share

  431. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    >> Share

    April 2023
  432. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    >> Share

  433. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    >> Share

  434. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    >> Share

  435. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    >> Share

  436. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    >> Share

  437. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    >> Share

  438. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    >> Share

  439. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    >> Share

  440. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    >> Share

  441. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    >> Share

  442. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    >> Share

  443. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    >> Share

  444. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    >> Share

  445. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    >> Share

  446. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    >> Share

  447. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    >> Share

    March 2023
  448. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    >> Share

  449. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    >> Share

  450. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    >> Share

  451. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    >> Share

  452. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    >> Share

  453. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    >> Share

  454. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    >> Share

  455. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    >> Share

  456. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    >> Share

  457. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    >> Share

  458. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    >> Share

  459. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    >> Share

  460. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    >> Share

  461. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    >> Share

  462. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    >> Share

  463. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    >> Share

  464. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    >> Share

    February 2023
  465. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    >> Share

  466. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    >> Share

  467. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    >> Share

  468. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    >> Share

  469. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    >> Share

  470. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016